Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the ...

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Growth came from Crohn’s disease treatments Skyrizi and Rinvoq, with each seeing sales rising 50% or more, offsetting Humira’s patent cliff. The two already own half the market. With $18.5 ...

AbbVie (NYSE:ABBV) has recently seen promising developments with the release of favorable final results from the MIRASOL trial of ELAHERE, demonstrating significant improvements for women with ...

AbbVie's newer immunology treatments Skyrizi and Rinvoq have shown impressive growth, with combined sales increasing 51% and 50%, respectively, in 2024. Management expects these drugs to reach $31 ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.